A-SEEDS
Matsumoto, JP · 3 known investors
Find your way into A-SEEDS
A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments. The company focuses on advancing basic research through non-clinical development into clinical application of these cancer cell therapies.
Founders & leadership
YN
Yozo NakazawaFounder & Director; Professor, Department of Pediatrics, Shinshu University
SY
Shigeki YagyuinRepresentative Director (CEO)Shigeki Yagyu is a pediatric oncologist and professor at Shinshu University who has led research on cell and gene therapies for cancer, including CAR-T and NK cell development. He completed postdoctoral training in adoptive cell therapy at Baylor College of Medicine's Center for Cell and Gene Therapy and holds patents in CAR-expressing immune cell technologies; he joined A-SEEDS as Representative Director in 2022 to advance non-viral CAR-T cell therapies toward clinical application.
TA
Takuji AchihaChief Development Officer
KT
Kiyohito TaniChief Operating Officer
Investors · 3
Frequently asked questions
- What does A-SEEDS do?
- A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments. The company focuses on advancing basic research through non-clinical development into clinical application of these cancer cell therapies.
- Who founded A-SEEDS?
- A-SEEDS was founded by Yozo Nakazawa.
- Who are A-SEEDS's investors?
- A-SEEDS's investors include Delight Ventures, Nippon Venture Capital, OSAKA University Venture Capital.
- Where is A-SEEDS headquartered?
- A-SEEDS is headquartered in Matsumoto, JP.